DDInter1251 DDInter1763
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis.[A180799,A180805] Previously, mycophenolic acid
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) KIAA0355
KIAA0355 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) MAP3K4
MAP3K4 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) MPC2
MPC2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) causes {v} (Side Effect) Ecchymosis
Ecchymosis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Mycophenolate mofetil {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Mycophenolate mofetil (Compound) upregulates KIAA0355 (Gene) and KIAA0355 (Gene) is upregulated by Temsirolimus (Compound)
Mycophenolate mofetil (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Mycophenolate mofetil (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Temsirolimus (Compound)
Mycophenolate mofetil (Compound) downregulates MAP3K4 (Gene) and MAP3K4 (Gene) is downregulated by Temsirolimus (Compound)
Mycophenolate mofetil (Compound) upregulates MPC2 (Gene) and MPC2 (Gene) is downregulated by Temsirolimus (Compound)
Mycophenolate mofetil (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Temsirolimus (Compound)
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)